An unusual recurrent high-grade glioneuronal tumor with MAP2K1 mutation and CDKN2A/B homozygous deletion

Barry Cheaney 2nd; Stephen Bowden; Katie Krause; Emily A Sloan; Arie Perry; David A Solomon; Seunggu Jude Han; Matthew D Wood

doi:10.1186/s40478-019-0763-x

An unusual recurrent high-grade glioneuronal tumor with MAP2K1 mutation and CDKN2A/B homozygous deletion

Acta Neuropathol Commun. 2019 Jul 9;7(1):110. doi: 10.1186/s40478-019-0763-x.

Authors

Barry Cheaney 2nd¹, Stephen Bowden², Katie Krause², Emily A Sloan³, Arie Perry³, David A Solomon³, Seunggu Jude Han², Matthew D Wood⁴

Affiliations

¹ School of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
² Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA.
³ Department of Pathology, University of California San Francisco, San Francisco, California, USA.
⁴ Department of Pathology, Oregon Health & Science University, Mail Code L-113, 3181 SW Sam Jackson Park Road, Portland, OR, 97202, USA. [email protected].

No abstract available

Keywords: Anaplastic; CDKN2A/B homozygous deletion; Glioneuronal tumor; MAP2K1 mutation; Multinodular and vacuolating neuronal tumor of the cerebrum; Next-generation sequencing.

Publication types

Case Reports
Letter

MeSH terms

Aged
Brain Neoplasms / diagnostic imaging
Brain Neoplasms / genetics*
Cyclin-Dependent Kinase Inhibitor p15 / genetics*
Cyclin-Dependent Kinase Inhibitor p16 / genetics*
Ganglioglioma / diagnostic imaging
Ganglioglioma / genetics*
Gene Deletion
Homozygote
Humans
MAP Kinase Kinase 1 / genetics*
Male
Mutation / genetics
Neoplasm Grading / methods
Neoplasm Recurrence, Local / diagnostic imaging
Neoplasm Recurrence, Local / genetics*

Substances

CDKN2A protein, human
CDKN2B protein, human
Cyclin-Dependent Kinase Inhibitor p15
Cyclin-Dependent Kinase Inhibitor p16
MAP Kinase Kinase 1
MAP2K1 protein, human